References
Sakakibara M, Nagashima T, Kadowaki M, et al. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol. 2009;16(9):2470–8.
Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol. 2009;27(8):1337–8.
Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16(7):1771–82.
Roukos DH. Radiation therapy for breast cancer. N Engl J Med. 2009;360(13):1362–3.
Roukos DH. Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg. 2009;249(6):1067–8.
Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn. 2009;9(3):227–9.
Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn. 2009;9(3):217–21.
Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol. 2009;16(10):2678–81.
Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther. 2009;9(4):389–92.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ziogas, D., Harissis, H. & Batsis, C. Node Micrometastases Detection After Neoadjuvant Chemotherapy in Breast Cancer: Is It of Clinical Value?. Ann Surg Oncol 17, 933–934 (2010). https://doi.org/10.1245/s10434-009-0746-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-009-0746-4